In vitro assessment of electronic nicotine delivery system (ENDS) aerosols

April 24, 2024

Dr Alexandra Noël speaks about using in vitro assays to assess the electronic nicotine delivery system aerosols. 

What you’ll learn: 

  • Overview of EVALI outbreak and harm caused.
  • Known effects of e-cigarettes.
  • How Air-liquid interface (ALI) physiologically relevant in vitro models can be used to assess the pulmonary effects associated with exposure to inhaled e-cig aerosols containing nicotine.

Watch the Recording

About our Speaker:

Dr. Alexandra Noël received her bachelor’s degree in Biomedical Sciences, her master’s in Occupational and Environmental Health, as well as her PhD in Public Health, with a specialization in Toxicology and Risk Assessment, all from the Faculty of Medicine of the University of Montreal (Quebec, Canada). She completed her post-doctoral training at Louisiana State University (LSU). Dr. Noël is currently an Associate Professor in the Department of Comparative Biomedical Sciences of the School of Veterinary Medicine at LSU. She conducts inhalation toxicology studies on cardio-pulmonary effects of in utero and adult exposures to second-hand cigarette smoke, electronic-cigarette aerosols, and nanoparticles. Her publication record includes 38 peer-reviewed scientific articles that generated over 575 citations, and more than 75 oral and poster presentations at national and international scientific conferences. Dr. Noël’s laboratory is presently funded by the NIEHS and the NHLBI to conduct research on electronic-cigarette aerosols and cardio-pulmonary toxicity in vitro and in vivo. In addition, Dr. Noël is the Manager of the LSU Inhalation Research Facility and the Leader of the Inhalation Toxicology Core of the LSU Superfund Research Program. Further, Dr. Noël is an Associate Editor for the American Journal of Respiratory Cell and Molecular Biology. Also, she is the co-Chair of the American Thoracic Society (ATS) Membership Committee, and she serves on the Society of Toxicology (SOT) Education and Career Development Committee (ECDC).


In 2019, there was an outbreak of e-cigarette (e-cig) or vaping-associated lung injury (EVALI) across the U.S., with more than 2,800 cases of lung injury. This clearly demonstrates that all e-cigs are not ‘safe’, and more research on vaping health outcomes is urgently needed. The EVALI outbreak was associated predominantly with the presence of vitamin E acetate in tetrahydrocannabinol (THC)-containing products. However, EVALI was also observed in nicotine exclusive e-cig users. Currently, both the short- and long-term pulmonary effects induced by the inhalation of e-cig aerosols are largely unknown. In this presentation, we will show how air-liquid interface (ALI) physiologically relevant in vitro models can be used to assess the pulmonary effects associated with exposure to inhaled e-cig aerosols containing nicotine.

About ScitoVation:

ScitoVation helps clients assess chemical compound safety using innovative science, next-generation technology, and professional expertise. ScitoVation is known for partnership, flexibility, and proven success in its work to develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals and consumer products. A spin-off of the former The CIIT and The Hammer Institutes for Chemical & Drug Safety Sciences, ScitoVation is an industry leader of New Approach Methods (NAMS) for chemical/drug discovery & development in the rapidly evolving global regulatory landscape.